New insights into the role of TREM2 in Alzheimer's disease

M Gratuze, CEG Leyns, DM Holtzman - Molecular neurodegeneration, 2018 - Springer
Alzheimer's disease (AD) is the leading cause of dementia. The two histopathological
markers of AD are amyloid plaques composed of the amyloid-β (Aβ) peptide, and …

Treatment of Alzheimer's disease and blood–brain barrier drug delivery

WM Pardridge - Pharmaceuticals, 2020 - mdpi.com
Despite the enormity of the societal and health burdens caused by Alzheimer's disease
(AD), there have been no FDA approvals for new therapeutics for AD since 2003. This …

A genetically encoded fluorescent acetylcholine indicator for in vitro and in vivo studies

M **g, P Zhang, G Wang, J Feng, L Mesik… - Nature …, 2018 - nature.com
The neurotransmitter acetylcholine (ACh) regulates a diverse array of physiological
processes throughout the body. Despite its importance, cholinergic transmission in the …

Multi-target design strategies for the improved treatment of Alzheimer's disease

P Zhang, S Xu, Z Zhu, J Xu - European journal of medicinal chemistry, 2019 - Elsevier
Alzheimer's disease (AD) is a multifactorial syndrome resulting in profound misery and
poses a substantial burden on human health, economy, and society throughout the world …

Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's …

DD Li, YH Zhang, W Zhang, P Zhao - Frontiers in neuroscience, 2019 - frontiersin.org
To study the impact of donepezil, rivastigmine, galantamine, and memantine on cognitive,
functional, behavioral, global changes and adverse effects in patients with mild, moderate …

[HTML][HTML] Recent advances in the neurobiology and neuropharmacology of Alzheimer's disease

K Kumar, A Kumar, RM Keegan… - Biomedicine & …, 2018 - Elsevier
Alzheimer's disease (AD) is an age-related neurodegenerative disorder characterized by
progressive deterioration of cognitive functions. The pathological hallmarks are extracellular …

Benzimidazole-based schiff base hybrid scaffolds: a promising approach to develop multi-target drugs for alzheimer's disease

R Hussain, S Khan, H Ullah, F Ali, Y Khan, A Sardar… - Pharmaceuticals, 2023 - mdpi.com
A series of benzimidazole-based Schiff base derivatives (1–18) were synthesized and
structurally elucidated through 1H NMR, 13C NMR and HREI-MS analysis. Subsequently …

Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease

J Prickaerts, PRA Heckman… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Phosphodiesterase (PDE) inhibitors improve signaling pathways in brain
circuits by increasing intracellular cyclic adenosine monophosphate (cAMP) and/or cyclic …

Alzheimer's disease and language impairments: social intervention and medical treatment

B Klimova, P Maresova, M Valis, J Hort… - Clinical interventions in …, 2015 - Taylor & Francis
Communication is very important for people to be successfully integrated into social
environment and make and maintain relationship. Particularly, language difficulties lead to …

A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease

YP Singh, H Rai, G Singh, GK Singh, S Mishra… - European Journal of …, 2021 - Elsevier
Alzheimer's disease (AD) is an age-related multifactorial neurodegenerative disorder
characterized by severe central cholinergic neuronal loss, gradually contributing to cognitive …